



Date: June 30, 2025

To,
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001

Scrip Code: 544353
Trading Symbol: AMWILL

Sub: Press Release dated 30th June, 2025

Dear Sir/ Ma'am,

Sub.:

Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI Listing Regulations**"), we hereby provide a copy of the Press Release titled "**Strategic Expansion Across Key States, New Product launch and Strengthening Financial Position**".

The above information will also be made available on the Company's website at www.amwillhealthcare.com.

You are requested to take above information on record.

Yours Faithfully,

Thanking You.
FOR AMWILL HEALTH CARE LIMITED

Anshu Anshuman
Company secretary and compliance Officer
ACS65515
Address: No. 90,4th Floor, 2nd Main, 7th Cross, Chamrajpet,
Bangalore, Karnataka, India, 560018

Place: Bangalore



“PRESS RELEASE”

Subject: Strategic Expansion Across Key States, New Product launch and Strengthening Financial Position

Bangalore, June 30, 2025: Amwill Healthcare Limited is pleased to share that it continues to **maintain a robust and well-established presence in Karnataka**, supported by **consistent and encouraging growth in Andhra Pradesh and Telangana**.

In line with its strategic growth roadmap, **the Company has further expanded its operations into key high-potential markets, including Maharashtra, Tamil Nadu, North East India, Chhattisgarh, and Madhya Pradesh**. To support this expansion, Amwill has strengthened its field force through the appointment of a National Sales Manager, Product Manager, Regional Managers, Area Sales Managers, and Medical Representatives. With the team now fully mobilized, operations have successfully commenced across all newly entered territories.

These newly entered markets appear promising, and are expected to contribute meaningfully to the Company’s revenue (topline) and profitability (bottom line) in the coming years. This expansion aligns with the Company’s long-term vision of building a strong pan-India presence in the dermatological and cosmeceutical segment.

In addition to its geographical expansion, **the Company has also recently launched a new dermatological innovation – UVBREAK Fusion Water Sunscreen**. This scientifically advanced formulation is developed using fusion water technology, offering rapid absorption, a non-greasy and non-comedogenic finish, and zero white cast, making it ideal for daily use, even on sensitive skin. The product has been well-received by dermatologists and end users, further strengthening Amwill’s growing cosmeceutical portfolio.

Amwill Healthcare Limited continue to maintain its strong financial foundation. The Company has remained completely debt-free since inception and continues to maintain a strong cash position. Amwill maintains fund base of more than ₹50 crore* in the form of bank balances, fixed deposits, and debt-oriented mutual fund investments. These financial resources will be strategically utilised to support the current expansion and any future planned expansions, ensuring sustained growth while maintaining financial discipline.

The Company remains committed to leveraging its robust financials, experienced team, and product strength to drive long-term shareholder value.

** As per the latest available audited financial statements.*